SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 06/30/2025 at 07:30, 8 months 26 days ago

Press release: Availability of the Q2 2025 Aide mémoire
Sanofi releases Q2 2025 Aide mémoire for financial modelling, to be published on July 31, 2025. Company details its commitment to innovation and impact in healthcare

Innovation Sanofi Aide Mémoire Financial Modelling Q2 2025
BRIEF

published on 06/25/2025 at 07:05, 9 months 1 day ago

Riliprubart Granted Orphan Drug Designation in the United States

FDA Immunology Orphan Drug Riliprubart Kidney Transplant
PRESS RELEASE

published on 06/25/2025 at 07:00, 9 months 1 day ago

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Sanofi's riliprubart granted orphan drug designation by FDA for antibody-mediated rejection in solid organ transplantation, addressing critical unmet need in transplant medicine

Orphan Drug Designation Sanofi Riliprubart Antibody-mediated Rejection Solid Organ Transplantation
BRIEF

published on 06/23/2025 at 07:05, 9 months 3 days ago

Sarclisa Gains EU Recommendation for Multiple Myeloma Treatment

Multiple Myeloma Phase 3 Study Sarclisa CHMP Approval Induction Therapy
PRESS RELEASE

published on 06/23/2025 at 07:00, 9 months 3 days ago

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by CHMP for transplant-eligible newly diagnosed multiple myeloma based on GMMG-HD7 study. Potential to improve outcomes in frontline setting globally

Multiple Myeloma Sarclisa EU Approval GMMG-HD7 Study CHMP Recommendation
BRIEF

published on 06/20/2025 at 07:05, 9 months 6 days ago

FDA Approves Dupixent for Bullous Pemphigoid Treatment

FDA Approval Dupixent Type 2 Inflammation Bullous Pemphigoid Rare Skin Disease
PRESS RELEASE

published on 06/20/2025 at 07:00, 9 months 6 days ago

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Dupixent approved in the US as the only targeted medicine for bullous pemphigoid, meeting the critical treatment needs of patients with uncontrolled disease

FDA Approval Chronic Disease Dupixent Type 2 Inflammation Bullous Pemphigoid
BRIEF

published on 06/17/2025 at 13:45, 9 months 8 days ago

Sanofi Successfully Prices €1.5 Billion Bond Issue

Bond Issue Corporate Financing Sanofi Fixed-rate Notes Euro Medium Term Note
PRESS RELEASE

published on 06/17/2025 at 13:40, 9 months 8 days ago

Press release: Sanofi successfully prices €1.5 billion bond issue
Sanofi successfully prices €1.5 billion bond issue with fixed-rate notes across 2 tranches, using proceeds for general corporate purposes, led by Citigroup and RBC Capital Markets, under Euro Medium Term Note Programme

Financial Markets Bond Issue Sanofi Euro Medium Term Note Programme Fixed-rate Notes
PRESS RELEASE

published on 06/16/2025 at 22:40, 9 months 9 days ago

Sanofi: Disclosure of trading in own shares

Published on 03/26/2026 at 12:59, 2 minutes ago

Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 12:45, 16 minutes ago

Quartz Mountain Reports Strong Warrant Exercise Participation and Provides Exploration Update at Maestro Project, Central British Columbia
Published on 03/26/2026 at 12:45, 16 minutes ago

Electric Royalties Provides Update on Critical Metals Royalty Portfolio
Published on 03/26/2026 at 12:40, 21 minutes ago

Sintana Announces Amendments to its By-Laws
Published on 03/26/2026 at 12:30, 31 minutes ago

Nextech3D.ai Expands Blockchain Ticketing Payments to Apple Pay and Google Pay, Advancing Platform Readiness for Adoption

View all ACCESSWIRE

Published on 03/26/2026 at 12:45, 15 minutes ago

Original-Research: CLINUVEL Pharmaceuticals Limited (von Parmantier & Cie. GmbH): Buy
Published on 03/26/2026 at 12:20, 40 minutes ago

North Peak Closes Second and Final Tranche of Previously Announced Non-Brokered Private Placement, Raising Total Funds of $5.675 Million
Published on 03/26/2026 at 12:17, 43 minutes ago

Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 03/26/2026 at 12:05, 56 minutes ago

Artlist Expands Its AI Platform with Professional-Grade AI Music for Video Production
Published on 03/26/2026 at 11:56, 1 hour 5 minutes ago

IVU continues its growth trajectory in the 2025 financial year

View all EQS

Published on 03/26/2026 at 08:57, 4 hours 3 minutes ago

Edenred statement
Published on 03/26/2026 at 07:30, 5 hours 31 minutes ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:53, 18 hours 8 minutes ago

LNA SANTE : 2025 Annual Results
Published on 03/25/2026 at 18:31, 18 hours 30 minutes ago

Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 19 hours 16 minutes ago

Combined General Meeting on May 05, 2026: publication of the notice of Meeting

View all LES ECHOS COMFI WIRE

News